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Summary In a study of 154 neuroblastomas, loss of heterozygosity (LOH) was observed on lp (13%, 19/143),
llq (19%, 11/59), 14q (15%, 15/97), 17p (5%, 5/105) and 17q (17%, 9/52). We also found an increase in
NM23HJ copy number in 14% (13/95) of neuroblastomas. All except one tumour with an increased copy
number stained positive with anti-NM23H1 monoclonal antibody. Event-free survival (EFS) was significantly
shorter in 19 patients with LOH on lp than in 128 without (41% vs 77% 4 year EFS, P=0.0093), and in 13
patients with increased NM23H1 copy numbers than in 82 with normal copy numbers of the gene (61% vs
84% 4 year EFS, P=0.0103). LOH on llq, 14q or 17q did not affect EFS. Most tumours with LOH on lp,
increased NM23HI copy numbers or MYCN amplification occurred in patients aged 12 months or more, those
with advanced stage disease, and those who showed near diploidy or pseudodiploidy. However, LOH on lp
was found in only 1 of the 13 tumours with increased NM23HJ copy numbers, and MYCN amplification of
four copies occurred in only one other such tumour. These findings suggest that the increased NM23HJ copy
number may be a predictor for poor prognosis, independent of LOH on lp, and probably also of MYCN
amplification.
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Molecular genetic studies ofneuroblastoma have suggested the
presence of a tumour-suppressor gene on lp36 (Fong et al.,
1989, 1992; Weith et al., 1989). We and other investigators have
recently reported that another tumour-suppressor gene on
lp32- lp34 may be closely associated with a biologically
aggressive subtype of neuroblastoma (Takeda et al., 1994;
Schleiermacher et al., 1994). Furthermore, two other tumour-
suppressor genes associated with the development and/or
progression of neuroblastoma are thought to be located on
1 lq and 14q (Fong et al., 1992; Srivatsan et al., 1993; Suzuki et
al., 1989; Takayama et al., 1992).
The NM23 gene was identified as a metastasis-suppressor
gene by differential hybridisation between two murine
melanoma sublines with low and high metastatic potential
(Steeg et al., 1988). The gene codes for the nucleoside
diphosphate kinase protein, and is located on 17q21-22
(Gilles et al., 1991; Varesco et al., 1992). Reduced expression
of NM23 was associated with lymph node metastases and
poor prognosis in breast cancer (Bevilacqua et al., 1989). In
contrast, overexpression, mutation and amplifiction of NM23
were reported in aggressive neuroblastomas (Hailat et al.,
1991; Leone et al., 1993; Chang et al., 1994).
We studied the loss of heterozygosity (LOH) on Ip, 1llq,
14q, 17p and 17q in 154neuroblastomas and found LOH on Ip,
1 lq, 14q and 17q in incidences ranging between 13% and 19%,
but that on 17p, where a tumour-suppressor gene TP53 is
located (Human Gene Mapping, 1991), in only 5%. In
addition, we examined NM23H1 copy markers in 95
neuroblastomas and found that there was an increase in the
copy number in 14% ofthe tumours. Event-free survival (EFS)
was examined between patients with LOH on Ip, 1 lq, 14q or
17q and those without, and between patients with increased
NM23HI copy numbers and those without. The results
indicated that only allelic loss on lp and increased NM23HJ
copy number predicted an adverse treatment outcome.
Materials and methods
Tissue samples
Tumours were obtained from 154Japanese infants and children
aged between 10 days and 9 years who were consecutively
admitted to various institutions (listed in the Acknowledge-
ments) between May 1985 and December 1993. One-hundred
and twenty-five tumours were obtained at diagnosis, 25 after
induction therapy and four at relapse. One-hundred and forty
tumours were obtained from the primary sites and 14 from
metastatic sites (five from bone marrow, seven from metastatic
lymph nodes and two from pleural effusion). Normal tissues
were obtained from peripheral blood of the same patients. Of
the 154 tumours, 152 were histologically classified as
neuroblastoma or ganglioneuroblastoma, and two as gang-
lioneuroma. Patients were staged according to the Evans
staging system (Evans et al., 1971). Patients in stage I or II were
treated with either surgery alone or surgery plus chemotherapy
consisting ofcyclophosphamide and vincristine; those in stage
III or IV were treated with multidrug chemotherapy consisting
of cyclophosphamide, vincristine, pirarubicin, cisplatin and
etoposide with or without surgery.
Molecular studies
Genomic DNA was extracted from the tumour tissue and
peripheral blood using standard phenol/chloroform proce-
dures. An aliquot of 3 -8 ig of DNA from each sample was
digested with appropriate restriction enzymes, electrophor-
esed through 0.6-0.8% agarose gels and transferred onto
nylon membranes (Hybond N+, Amersham, Tokyo) by
alkaline blottings.
The 22 probes used to detect allelic loss included D1S7
(MS1) on lp, D1IS146 (pHBI59), D1IS29 (L7), CD3D
(pPGBC9), CD3E (pDJ4), PBGD (PBGD), Dl1S147
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copynumber as an increase in the radioactivity ofthe NM23HJ
fragments of tumour tissue relative to both D81B2.0 and
D14S23 to more than 150% compared with that of the
corresponding fragments of normal tissue (Figure 1).
PCR-SSCP (polymerase chain reaction-single strand
conformation polymorphism) analysis was performed on
three tumours that showed LOH on 17p, using pairs of
primers to detect mutations of exons 5, 6, 7 and 8 of TP53
(Murakami et al., 1991).
NM23H1
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Figure 1 Southern blots of BglII-digested DNA of normal (N)
and tumour (T) tissues from two patients (nos. 797 and 1126).
The same filters were successively hybridised with the NM23HJ,
D81B2.0 and D14S23 probes. The radioactivity of the NM23HJ
fragments relative to that of the D81B2.0 or D14S23 fragment
was compared in tumour and normal tissues. The NM23HJ copy
numbers of tumour 797 relative to that of the normal tissue were
2.8 and 2.0 when D81B2.0 and D14S23 were used as internal
controls of one copy respectively, and those of tumour 1126 were
1.9 and 1.6 respectively.
(HBI18P1), DIIS286 (phage 8- 10), DlIS382 (CJ52.12),
D11S383 (CJ52.15) on llq, INS (pHINS6.0) and D11S151
(p56H2.4) on lip, ANG (ANG), D14S13 (pMLJ14), D14S1
(pAWl0l), D14S17 (pEFZ18.2), D14S16 (pTHH37), D14S23
(cKKA39), D14S19 (pHHH208) and D14S20 (pMCOC12) on
14q and D17S30 (pYNZ22) on 17p (Human Gene Mapping,
1991). The NM23HJ probe, specifically hybridising to the
NM23HJ gene (Okada et al., 1994), was used for detection of
allelic loss on 17q and determination of the NM23HJ copy
number. D81B2.0 [an intron fragment from MTG8 on
chromosome 8 with no restriction fragment length poly-
morphisms (RFLP) site for Bglll] and D14S23 were used as
an internal control for one copy. Presence or absence of
MYCN amplification was examined with the probe NB-19-
21, and probe no. 8 or ERBB2 was used as an internal
control. The DNA probes were labelled with [32P]dCTP by
the random priming method (Feinberg and Vogelstein, 1983).
Hybridisation was carried out as described previously
(Takeda et al., 1994).
Autoradiography and quantification of radioactivity were
performed using a bioimage analyser (FUJIX BAS 2000).
The radioactivity of an RFLP fragment relative to that of
another fragment of the same sample was compared in
tumour and normal tissues. We defined allelic loss as a
reduction in the relative radioactivity of one fragment of
tumour tissue to less than 50% compared with that of the
corresponding fragment of normal tissue.
The radioactivity ofthe NM23HJ fragments relative to that
ofthe D81B2.0 and D14S23 fragments was compared between
tumour and normal tissues. We defined an increased NM23H1
Immunohistochemical studies
Avidin-biotin complex (ABC) immunoperoxidase assay was
performed on 4 yim sections from formalin-fixed, paraffin-
embedded tissues. Tissue sections were deparaffinised,
rehydrated and exposed to 0.3% hydrogen peroxide in
methanol to eliminate endogenous peroxidase activity.
Sections were incubated with monoclonal anti-human
NM23H 1 antibody (Seikagaku, Tokyo, Japan) diluted
1:300 in phosphate-buffered saline (PBS) for 18 h at 4°C.
The specificity of the antibody was proved by immunopre-
cipitation and immunoblotting (Urano et al., 1993). The ABC
assay was performed using CSA kits (Dako, CA, USA). The
end-products were visualised by treating the sections with
diaminobenzidine tetrahydrochloride. Negative controls were
performed with normal mouse or rabbit serum instead of the
primary antibody. The slides were scored without knowledge
of the NM23HJ gene analysis and before compilation of the
clinical data. Three categories were used in scoring the slides:
strong staining (+), weak staining (±), no staining (-) of
tumour cells. Only tumours with strong staining were
considered to have a positive reaction.
Chromosome studies
The tumour tissue was minced with scissors and was
cultured in plastic flasks containing ES medium (Nissui,
Seiyaku, Tokyo) with 15% fetal calf serum. The cells were
harvested within 96 h from the start of culture. Bone
marrow cells were cultured for 24 h in plastic flasks
containing RPMI-1640 medium with 20% fetal calf serum,
and were harvested. Chromosomes were analysed by regular
Giemsa staining and Q- and/or G-banding techniques. We
defined abnormal clones and chromosome ploidies according
to ISCN (1991). When we found only normal diploid
metaphase cells in tumour tissues, the examination was
considered to have failed to detect malignant mitotic cells
and, hence, to be inadequate.
Statistical analyses
The EFS for each group of patients was estimated by the
Kaplan-Meier method (Kaplan and Meier, 1958) on the data
updated on 30 April, 1995; and differences in EFS curves were
assessed using the generalised Wilcoxon and log-rank tests
(Gehan, 1965; Peto and Peto, 1972). Significance of the
differences in various clinical and biological aspects of the
disease between patients with LOH on lp and those without,
and between patients with an increased NM23H1 copy number
and those without, was examined by the chi-square or Fisher's
exact test.
Results
Allelic loss on) p, JJq, 14q, 17p or 17q, and NM23H1 copy
numbers
One hundred and forty-seven of the 154 patients were
informative at D1S7 on lp, and 19 of the 147 informative
patients (13%) showed LOH on lp. Fifty-nine of the 102
patients were informative at one or more loci on chromosome
1 lq, and 11 ofthe 59 informative patients (19%) showed LOH
on lq. The results for the 11 tumours are summarised in
Figure 2. As tumours 694 and 804 retained heterozygosity at
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DliS383 and DlIS146 respectively, the commonly deleted
region on 1 lq was distal to DlIS146 and proximal to Dl 1S383.
Ninety-six of the 107 patients were informative at one or
more loci on chromosome 14q, and 15 of the 96 informative
15
1.
patients (16%) showed LOH on 14q. The results for the 15
tumours are summarised in Figure 3. As tumours 882 and
955 retained heterozygosity at D14S13 and tumour 998
retained that at D14S1, the consensus deletion on 14q
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Figure 2 LOH on 1 lq and lp in 11 neuroblastomas. The closed and open circles indicate LOH and no LOH respectively, and the
shaded circle indicates 'uninformative.'
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Figure 3 LOH on 14q in 15 neuroblastomas. The closed and open circles indicate LOH and no LOH respectively, and the shaded
circle indicates 'uninformative.'
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aencompassed the region distal to D14S13 and proximal to
D14S1. One hundred and five of the 122 patients were
informative at D17S30 on chromosome 17p, and only 5 of
the 105 (5%) showed LOH at the D17S30 locus. Fifty-two of
the 97 patients were informative at the NM23HJ locus on
17q, and 9 of the 52 patients (17%) showed LOH on 17q.
PCR-SSCP analysis was performed on three tumours
(nos. 841, 1152 and 1185) with LOH on 17p, and showed
abnormal motilities of fragments, representing exon 7 of
TP53 in polyacrylamide gel, in one (no. 1152) of them.
The NM23HJ copy number was examined in 95 patients,
and 13 of the 95 (14%) showed increased copy numbers
ranging from 1.5 to 4.4 (Figure 1).
Immunohistochemical staining with anti-NM23HI monoclonal
antibody
NM23H1 protein expression was demonstrated in 11 of the
29 patients whose tumour tissues were examined (Figure 4),
in 7 of 8 tumours with the increased NM23HJ copy number,
and in 4 of 21 tumours with the normal copy number
(P=0.0014 by Fisher's exact test) (Table III).
Event-free survival
One hundred and fifty-four patients were classified into
groups on the basis of age, stage, outcome of mass screening
(Sawada et al., 1984) and ploidy of tumours. They were also
classified by presence or absence of MYCN amplification,
NM23HI and nouroblastoma
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LOH on Ip, llq, 14q and 17q, and increased NM23HJ copy
numbers. EFS at 4 years in each group of patients is shown
in Table I. There were significant differences in the survival
time between the patients classified by age, stage, outcome of
mass screening, ploidy of tumours, presence or absence of
MYCN amplification, LOH on lp and the increased
Figure 4 Tumour 482 stained with anti-NM23H1 monoclonal
antibody. The nucleus was strongly stained. The tumour cells had
an increased copy number (x2) of the NM23HJ gene (ABC
method, x 100).
Table I Clinical and biological features of 154 children with neuroblastoma
No. (%) of Four year Log-rank Wilcoxon
patients %EFS S.E. P Generalised P
Age
A. < 12months 92 (60) 99 1 <0.0001 A vs B <0.0001
B. > 12months 62 (40) 57 8
Stage
A. I, II, IVs 74 (48) 100 0 <0.0001 A vs B <0.0001
B. III 31 (20) 63 11 A vs C 0.0050
C. IV 49 (32) 54 9 B vs C 0.0215
Mass screening
A. Positive 87 (56) 99 1 <0.0001 A vs B <0.0001
B. Negative 43 (30) 55 9 A vs C 0.0005
C. Not undergone 24 (16) 65 17 B vs C N.S.
Ploidy of tumours
A. 2n 31 (20) 57 12 0.0012 A vs B 0.0002
B. 3n 68 (44) 94 3 A vs C or D N.S.
C. 4n 6 (4) 75a 22 B vs C or D N.S.
D. No mitotic cells 49 (32) 81 8
MYCN amplification
A. Present 15 (10) 31 18 0.0002 A vs B 0.0082
B. Absent 138 (90) 87 3
LOH on lp
A. Present 19 (12) 41 13 0.0022 A vs B 0.0093
B. Absent 128 (83) 77 4 A vs C 0.0285
C. Not informative 7 (5) 100 0 B vs C N.S.
LOH on llq
A.Present 11 (11) 73 13 N.S. AvsBorC N.S.
B. Absent 48 (47) 76 7 B vs C N.S.
C. Not informative 43 (42) 71 7
LOH on 14q
A. Present 15 (14) 74 11 N.S. A vs B or C N.S.
B. Absent 81 (76) 74 5 B vs C N.S.
C. Not informative 11 (10) 82 12
LOH on 17q
A. Present 9 (9) 75 21 N.S. A vs B or C N.S.
B. Absent 43 (44) 91 5 B vs C N.S.
C. Not informative 45 (47) 76 9
NM23HJ copy number
A. Increased 13 (14) 61 15 0.0693 A vs B 0.0103
B. Normal 82 (86) 84 7
aThree year %EFS is shown. EFS, event-free survival; S.E., standard error; N.S., not significant.NM23H1 and neuroblastoma
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Table II Clinical characteristics, chromosome ploidy and MYCN amplification in neuroblastomas classified by presence or absence of LOH
on lp or increased NM23HJ copy numbers
Mass Stage of Chromosome MYCN
Group of No. of Age screeninga disease ploidy amplification
patients patients <12months >12months + - N I+II+IVs III IV 2n 4n 3n NM + -
IpLOH+b 19 4 15 4 11 4 3 4 12 11 1 3 4 10 8
IpLOH_b 128 82 46 78 31 19 66 26 36 19 5 62 42 7 121
NM23HI +cd 13 3 10 5 4 4 2 2 9 7 1 2 3 1 12
NM23H1_c,d 82 52 30 47 23 12 41 17 24 14 5 40 23 11 71
aMass screening: +, undergone the mass screening with a positive result; -, undergone the mass screening with a negative result; N, not
undergone the mass screening. 'There is a significant difference in the incidence ofpatients under.12months ofage (P=0.0006), in the incidence of
patients found by mass screening (P= 0.0136), in the stage distribution (P= 0.0142), in the ploidy distribution (P= 0.0071) and in the incidence of
patients with MYCNamplification (P<0.0001) between the patientswith LOH on Ip and thosewithout.cNM23HJ +, with an increasedNM23HJ
copy number; NM23HJ -, with a normal NM23HJ copy number. dThere is a significant difference in the incidence ofpatients under 12months of
age (P= 0.0129), in the stage distribution (P= 0.0158) and in the ploidy distribution (P= 0.0121) between the patients with an increased NM23HI
copy number and those without.
Table m Clinical, cytogenetic and genetic characteristics of 13 patients with increased NM23HJ copy numbers
MYCN NM23H1 Event-free
Age Primary copy immuno- Present survival
Patient (months) Mass screeninga Stage site Ploidy numbers staining status (months)"
482 12 + IV Adr. NM 1 + NED 74+
786 6 + IV Ret. 46c 1 + NED 50+
790d 43 - IV Ret. NM 1 + NED 50+
792 34 - IV Adr. 89 1 + DOD 24
797 67 N IV Adr. 46c 1 NE DOD 26
860 12 + IV Adr. 78 1 NE NED 36+
909e 72 _ IV Adr. 44C 1 NE DOD 0
912 18 - IV Adr. NM 4 + NED 47+
927 60 N IV Adr. 45 1 NE DOD 11
1036 8 + I Adr. 67 1 + NED 31+
1089 7 + III Ret. 55 1 + NED 27+
1126 54 N IV Pelv. 50 1 + AWD 6
1152 60 N III Ret. 53 1 NE NED 22+
aMass screening: +, undertone the mass screening with a positive result; -, undergone the mass screening with a negative result; N, not
undergone the mass screening. + after the number ofmonths indicates that thepatient was still alive. cKaryotypes are described in TableIV. dThe
tumour also showed LOH on Ip, 14q and 17q. eThe tumour also showed LOH on 14q. Adr., adrenal; Ret., retroperitoneum; Pelv., pelvic cavity;
NM, no good metaphases obtained; NED, no evidence ofdisease; DOD, died ofdisease; AWD, alive with disesase; NE, not examined.
NM23HI copy number (Figure 5), but no differences were
detected between patients classified by presence or absence of
LOH on llq, 14q or 17q.
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Clinical and biological characteristics ofpatients with LOH on
Ip or an increased NM23H1 copy number (Tables II and III)
There was a significant difference in the incidence of patients
under 12 months of age (P = 0.0006), in the stage
distribution (P= 0.0142), in the incidence of patients found
by mass screening (P=0.0136), in the ploidy distribution
(P=0.0071) and in the incidence of tumours with MYCN
amplification (P<0.0001) between patients with LOH on lp
and those without. There was a significant difference in the
incidence of patients under 12 months of age (P=0.0129),.in
the stage distribution (P=0.0158) and in ploidy distribution
(P=0.0121) between patients with increased NM23HI copy
number and those without. Clinical, cytogenetic and genetic
characteristics of 13 patients with increased NM23HJ copy
number are shown in Table III. Only 1 (no. 790) of the 13
patients with the increased NM23HI copy number showed
LOH on lp in the tumour.
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Figure 5 Event-free survival curves for two groups of patients
classified by presence or absence of an increased NM23H1 copy
number (P=0.0103). - - -, Normal NM23HJ copy number
(n =82); , increased NM23H1 copy number (n = 13).
Ploidies and karyotypes of tumours with an increased
NM23H1 copy number (Tables III and IV)
Modal chromosome numbers were determinable in 10 of the
13 tumours with increased NM23H1 copy number; seven had
near-diploidy or pseudodiploidy, two had near-triploidy and
the other had hypotetraploidy. Karyotypes were successfully
analysed in three of the ten tumours (Table IV). All three
tumours had hypo- or pseudodiploidy; two of them
apparently had a normal pair of chromosomes 17, and the
Table IV Karyotypes of neuroblastomas with increased NM23HJ
copy numbers
Modal
Tumour number Representative karyotype
786 46 46,XY,del(3)(q25q27),del(11)(q21q25),add(15)
(pl3),add(17)(q22),add(19)(q13),-20, +mar
797 46 46,XY,del(2)(p23),-5,del(13) (ql4q22),add(13)
(q34),-15,add(18)(q23),-20, + 3mar
909 44 44,XX,dic(1;20)(p36;ql3),-15,-18,-22, +2mar
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other showed an abnormal chromosome 17 with an unknown
fragment on 17q22.
Discussion
We found allelic loss on Ip, llq, 14q, 17p and 17q in 13%
(19/147), 19% (11/59), 16% (15/96), 5% (5/105) and 17% (9/
52) of neuroblastomas respectively. In previous studies on
neuroblastomas, the incidence of LOH on lp ranged from
25% to 89%, on llq was 28%, on 14q ranged from 22% to
40% and on 17p was 0% (Fong et al., 1989, 1992; Weith et
al., 1989; Takeda et al., 1994; Schleiermacher et al., 1994;
Srivatsan et al., 1993; Suzuki et al., 1989; Takayama et al.,
1992). The incidence of LOH on 17q has not been reported.
The incidences of LOH on Ip, 1 lq or 14q in our series were
lower than those previously reported on these three
chromosomal regions. The different incidences may have
been caused by the inclusion in our series of a large number
of patients found by mass screening. Our study defined the
locations ofputative tumour-suppressor genes of 1 lq and 14q
in the region distal to DlIS146 (llql3) and proximal to
D11S383 (l1q24-25) and in the region distal to D14S13 and
proximal to D14SI respectively. Both of the D14 loci were
mapped in 14q32, and the distance between D14S13 and
D14SI is estimated at 8 Mb (Nakamura et al., 1989).
We also found increased NM23HI copy numbers in 14%
(13/95) of neuroblastomas. The results were confirmed by
immunohistochemical staining using anti-NM23HI mono-
clonal antibody. The previous study reported increased
NM23HJ copy numbers in 23% (7/31) of neuroblastomas
(Leone et al., 1993). The same study reported no increase in
the copy number of NM23H2, which is located next to
NM23HI on 17q21 -22. Another study showed 17q
polysomy in 38% (20/53) of neuroblastomas using poly-
morphic DNA markers on 17q other than NM23HJ (Caron,
1995). Our cytogenetic study on the three tumours showed no
polysomy of 17q, and suggested that the limited chromoso-
mal region including the NM23HJ locus may have amplified
in the tumours.
We compared EFS of different groups ofpatients classified
by presence or absence of LOH in each of the four
chromosomal regions (i.e. lp, 1lq, 14q and 17q) in the
tumour and by presence or absence of an increased NM23HI
copy number. Only LOH on lp and an increased NM23HI
copy number proved to be predictors for adverse treatment
outcome. Most tumours with an increased NM23HJ copy
number occurred in patients aged 12 months or more with
advanced stage disease and who showed near-diploidy or
pseudodiploidy; these characteristics are similar to those
tumours with LOH on lp or with MYCN amplification
(Takeda et al., 1994). However, LOH on lp was found in
only 1 of the 13 tumours with an increased NM23HJ copy
number, and MYCN amplification of four copies was found
in only one other tumour (Table III). These findings indicate
that an increased NM23HJ copy number may be a predictor
for poor prognosis independent of LOH on lp and probably
also of MYCN amplification. Thus, by using various genetic
markers, including the copy numbers of MYCN and
NM23H1 and presence or absence of LOH on lp, we may
be able to predict the prognosis of neuroblastoma patients
more precisely than otherwise. Therapy should be intensified
in patients with positive results for these specified genetic
markers.
Acknowledgements
This work was supported in part by a Grant-in-Aid for a Creative
Basic Research (Human Genome Program) from the Ministry of
Education, Science and Culture, and by a Grant-in-Aid from the
Ministry of Health and Welfare of Japan.
We acknowledge Drs H Shiku and T Kozu for providing the
NM23HJ and D81B2.0 probes respectively. All other probes in our
study were obtained through the Japanese Cancer Research
Resources Bank or the American Type Culture Collection. We
also acknowledge T Matsui and A Tamura for expert technical
assistance in the immunohistochemistry.
We thank Dr T Oka, Asahikawa Medical College (Asahikawa,
Hokkaido); Dr Y Hatae, National Sapporo Hospital (Sapporo,
Hokkaido); Dr T Hirama, Hokkaido Children's Medical Center
(Otaru, Hokkaido); Dr A Watanabe, Akita University (Akita,
Akita); Dr A Kikuta, Fukushima Medical College (Fukushima,
Fukushima); Dr Y Tsunematsu, National Children's Hospital
(Setagaya-ku, Tokyo); Dr M Iwata, Nihon University (Itabashi-
ku, Tokyo); Dr J Yokoyama, Keio University (Shinjuku-ku,
Tokyo); Dr J Takayama, National Cancer Center (Chou-ku,
Tokyo); Dr A Hayashi, Kiyose Children's Hospital (Kiyose,
Tokyo); Drs H Nishihira and Y Tanaka, Kanagawa Children's
Medical Center (Yokohama, Kanagawa); Dr S Koizumi, Kana-
zawa University (Kanazawa, Ishikawa); Dr T Sakajiri, Fukui
Hospital (Fukui, Fukui); Drs Y Horikoshi and Y Hamazaki,
Shizuoka Children's Hospital (Shizuoka, Shizuoka); Dr H Kitou,
Seirei Hamamatsu Hospital, (Hamamatsu, Shizuoka); Dr Y
Hanji, Ichinomiya Municipal Hospital (Ichinomiya, Aichi); Dr
Y Miyajima, Nagoya University (Nagoya, Aichi); Drs S Mabuchi
and Y Imai, Hyogo Children's Hospital (Kobe, Hyogo); Drs M
Sakurai and H Kawasaki, Mie University (Tsu, Mie); Dr Y
Nakamura, Uwajima Municipal Hospital (Uwajima, Ehime); Dr
Y Ishida, Ehime University (Onsen-gun, Ehime); Dr K Matsu-
moto, Nagasaki University (Nagasaki, Nagasaki); Dr H Eguchi,
Kurume University (Kurume, Fukuoka); Dr G Urano, University
of Occupational and Environmental Health (Kitakyushu, Fukuo-
ka); and Dr J Okamura, Kyushu Cancer Center (Fukuoka,
Fukuoka) for providing samples, pathology slides and clinical
data.
References
BEVILACQUA G, SOBEL Mg, LIOTTA LA AND STEEG PS. (1989).
Association of low nm23 RNA levels in human primary
infiltration ductal breast carcinomas with lymph-node involve-
ment and other histopathological indicators of high metastatic
potential. Cancer Res., 49, 5185-5190.
CARON H. (1995). Allelic loss of chromosome 1 and additional
chromosome 17 material are both unfavourable prognostic
markers in neuroblastoma. Med. Pediatr. Oncol., 24, 215-221.
CHANG, CL, ZHU X, THORAVAL DH, UNGAR D, RAWWAS J, HORA
N, STRAHLER JR AND HANASH SM. (1994). nm23-HI mutation
in neuroblastoma. Nature, 370, 335-336.
EVANS AE, D'ANGIO DJ AND RANDOLPH J. (1971). A proposed
staging for children with neuroblastoma. Cancer, 27, 374-378.
FEINBERG AP AND VOGELSTEIN B. (1983). A technique for
radiolabeling DNA restriction endonuclease fragments to high
specific activity. Anal. Biochem., 132, 6- 13.
FONG CT, DRACOPOLI NC, WHITE PS, MERRILL PGT, GRIFFITH
RC, HOUSMAN DE AND BRODEUR GM. (1989). Loss of
heterozygosity for the short arm of chromosome 1 in human
neuroblastomas: correlation with N-myc amplification. Proc.
Natl Acad. Sci. USA, 86, 3753 -3757.
FONG CT, WHITE PS, PETERSON K, SAPIENZA C, CAVENEE WK,
KERM SE, VOGELSTEIN B, CANTOR AB, LOOK AT AND
BRODEUR GM. (1992). Loss of heterozygosity for chromosomes
1 or 14 defines subsets ofadvanced neuroblastomas. Cancer Res.,
52, 1780- 1785.
GEHAN E. (1965). A generalized Wilcoxon test for comparing
arbitrarily singly-censored samples. Biometrika, 52, 203-224.
GILLES AM, PRESECAN E, VONICA A AND LASCU I. (1991).
Nucleoside diphosphate kinase from human erythrocytes. J.
Biol. Chem., 266, 8784-8789.
HAILAT N, KEIM DR, MELHEM RF, ZHU X, ECKERSKORN C,
BRODEUR GM, REYNOLDS CP, SEEGER RC, LOTTSPEICH F,
STRAHLER JR AND HANASH SM. (1991). High levels of pl9/
nm23 protein in neuroblastoma are associated with advanced
stage disease and N-myc gene amplification. J. Clin. Invest., 88,
341 -345.
HUMAN GENE MAPPING 11. (1991). Cytogenet. Cell Genet., 58,
1440- 1569.
ISCN 1991. (1992). Guidelinesfor Cancer Cytogenetics. Supplement to
an International System for Human Cytogenetic Nomenclature.
Karger: Basle.NM23H1 and neuroblastoma
iv I0 Takeda et a!
1626
KAPLAN EL AND MEIER P. (1958). Nonparametric estimation for
incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
LEONE A, SEEGER RC, HONG CM, HU YY, ARBOLEDA MJ,
BRODEUR GM, STRAM D, SLAMON DJ AND STEEG PS. (1993).
Evidence for nm23 RNA overexpression, DNA amplification and
mutation in aggressive childhood neuroblastomas. Oncogene, 8,
855-865.
MURAKAMI Y, HAYASHI K AND SEKIYA T. (1991). Detection of
aberrations of the p53 alleles and the gene transcript in human
tumor cell lines by single-stranded conformation polymorphism
analysis. Cancer Res., 51, 3356-3361.
NAKAMURA Y, LATHROP M, O'CONNELL P, LEPPERT M, KAMBOH
MI, LALOUELJM AND WHITE R. (1989). Frequent recombination
is observed in the distal end of the long arm of chromosome 14.
Genomics, 4, 76-81.
OKADA K, URANO T, GOrT, BABA H, YAMAGUCHI A, FURUKAWA
K AND SHIKU H. (1994). Isolation of human nm23 genomes and
analysis of loss of heterozygosity in primary colorectal
carcinomas using a specific genomic probe. Cancer Res., 54,
3979-3982.
PETO R AND PETO J. (1972). Asymptotically efficient rank invariant
test procedures. J. R. Stat. Soc., (a), 135, 185-206.
SAWADA T, HIRAYAMA M AND NAKATA T. (1984). Mass screening
for neuroblastoma in infants in Japan. Lancet, 2, 271-273.
SCHLEIERMACHER G, PETER M, MICHON J, HUGOT J, VIELH P,
ZUCKER J, MAGDELENAT H, THOMAS G AND DELATTRE 0.
(1994). Two distinct deleted regions on the short arm of
chromosome 1 in neuroblastoma. Genes Chrom. Cancer, 10,
275-281.
SRIVATSAN ES, YING KL AND SEEGER RC. (1993). Deletion of
chromosome 11 and of 14q sequences in neuroblastoma. Genes
Chroms. Cancer, 7, 32-37.
STEEG PS, BEVILACQUA G, KOPPER L, THORGEIRSSON UP,
TALMADGE JE, LIOTTA LA AND SOBEL ME. (1988). Evidence
for a novel gene associated with low tumor-metastatic potential.
J. Natl Cancer Inst., 80, 200-204.
SUZUKI T, YOKOTA J, MUGISHIMA H, OKABE I, OOKUNI M,
SUGIMURA T AND TERADA M. (1989). Frequent loss of
heterozygosity on chromosome 14q in neuroblastoma. Cancer
Res., 49, 1094- 1098.
TAKAYAMA H, SUZUKI T, MUGISHIMA T, FUJISAWA T, OOKUNI
M, SCHWAB M, GEHRING M, NAKAMURA Y, SUGIMURA T,
TERADA M AND YOKOTA J. (1992). Deletion mapping of
chromosome 14q and lp in human neuroblastoma. Oncogene, 7,
1185- 1189.
TAKEDA 0, HOMMA C, MASEKI N, SAKURAI M, KANDA N,
SCHWAB M, NAKAMURA Y AND KANEKO Y. (1994). There
may be two tumor suppressor genes on chromosome lp closely
associated with biologically distinct subtypes of neuroblastoma.
Genes Chrom. Cancer, 10, 30-39.
URANO T, FURUKAWA K AND SHIKU H. (1993). Expression of
nm23/NDP kinase proteins on the cell surface. Oncogene, 8,
1371- 1376.
VARESCO L, CALIGO MA, SIMI P, BLACK DM, NARDINI V,
CASARINO L, ROCCHI M, FERRARA G, SOLOMON E AND
BEVILACQUA. (1992). The nm23 gene maps to human chromo-
some band 17q22 and shows a restriction fragment length
polymorphism with BgIIH. Genes Chrom. Cancer, 4, 84-88.
WEITH A, MARTINSSON T, CZIEPLUCH C, BRUDERLEIN S, AMLER
LC, BERTHOLD F AND SCHWAB M. (1989). Neuroblastoma
consensus deletion maps to lp36.1-2. Genes Chrom. Cancer, 1,
159-166.